Education
About Us
Working with TipRanks
Follow Us
Pfizer Inc (GB:0Q1N)
:0Q1N
0Q1N Stock Chart & Stats
Day’s Range― - ―
52-Week Range$20.77 - $29.82
Previous CloseN/A
Volume69.09K
Average Volume (3M)141.47K
Market Cap
$146.00B
Enterprise Value$186.89B
Total Cash (Recent Filing)$13.25B
Total Debt (Recent Filing)$61.80B
Price to Earnings (P/E)13.7
Beta1.00
Next Earnings
Nov 04, 2025EPS Estimate
0.67Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.78
Shares Outstanding5,685,550,300
10 Day Avg. Volume244,550
30 Day Avg. Volume141,465
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)1.70
Price to Sales (P/S)2.36
P/FCF Ratio15.28
Enterprise Value/Market Cap1.28
Enterprise Value/Revenue2.93
Enterprise Value/Gross Profit4.35
Enterprise Value/Ebitda8.21
Forecast
1Y Price Target
$28.47Price Target Upside12.57% Upside
Rating ConsensusHold
Number of Analyst Covering17
Bulls Say, Bears Say
Bulls Say
AcquisitionsThe Pfizer-Metsera acquisition is seen as successful due to high interest from multiple bidders, indicating strong potential in Metsera's pipeline.
Corporate StrategyPfizer's strategic acquisitions using COVID cash have strengthened its pipeline, bolstering a positive outlook for the company's future.
Financial PerformancePfizer shares are considered undervalued with potential for top-line growth and margin expansion, making it attractive compared to U.S. BioPharma peers.
Bears Say
Market CompetitionIncreased pricing pressure is expected for Vyndamax due to competition and Part D redesign.
Regulatory RisksPotential regulatory risks and delays are anticipated following the Pfizer-Metsera acquisition agreement.
Sales PerformanceSales of Paxlovid and Comirnaty are trending significantly below expectations, leading to lower sales estimates.
Pfizer News
0Q1N FAQ
What was Pfizer Inc’s price range in the past 12 months?
Pfizer Inc lowest share price was $20.77 and its highest was $29.82 in the past 12 months.
What is Pfizer Inc’s market cap?
Pfizer Inc’s market cap is $146.00B.
When is Pfizer Inc’s upcoming earnings report date?
Pfizer Inc’s upcoming earnings report date is Nov 04, 2025 which is in 25 days.
How were Pfizer Inc’s earnings last quarter?
Pfizer Inc released its earnings results on Aug 06, 2025. The company reported $0.78 earnings per share for the quarter, beating the consensus estimate of $0.58 by $0.2.
Is Pfizer Inc overvalued?
According to Wall Street analysts Pfizer Inc’s price is currently Undervalued.
Does Pfizer Inc pay dividends?
Pfizer Inc does not currently pay dividends.
What is Pfizer Inc’s EPS estimate?
Pfizer Inc’s EPS estimate is 0.67.
How many shares outstanding does Pfizer Inc have?
Pfizer Inc has 5,685,550,300 shares outstanding.
What happened to Pfizer Inc’s price movement after its last earnings report?
Pfizer Inc reported an EPS of $0.78 in its last earnings report, beating expectations of $0.58. Following the earnings report the stock price went down -2.439%.
Which hedge fund is a major shareholder of Pfizer Inc?
Currently, no hedge funds are holding shares in GB:0Q1N
Pfizer Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$28.47 (12.57% Upside)
$28.47 (12.57% Upside)
Blogger Sentiment
Bullish
GB:0Q1N Sentiment 70%
Sector Average 72%
Sector Average 72%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-10.52%
12-Months-Change
Fundamentals
Return on Equity
12.16%
Trailing 12-Months
Asset Growth
-4.67%
Trailing 12-Months
Company Description
Pfizer Inc
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
0Q1N Company Deck
0Q1N Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a positive sentiment overall, with Pfizer showing strong financial performance, significant advancements in its R&D pipeline, and effective cost management. However, there are some challenges, particularly related to pricing pressures from the IRA Medicare Part D redesign and competitive pressures in the oncology sector.View all GB:0Q1N earnings summaries0Q1N Revenue Breakdown
47.36% Primary Care
26.17% Specialty Care
24.54% Oncology
1.80% PFIZER CENTREONE
0.13% PFIZER IGNITE
0Q1N Stock 12 Month Forecast
Average Price Target
$28.47
▲(12.57% Upside)
Technical Analysis
Options Prices
Currently, No data available
---